Role of circulating tumour DNA in predicting complete clinical response and local regrowth after total neoadjuvant therapy for rectal cancer: meta-analysis.
Blood-based tumor DNA tests may help doctors decide whether patients with rectal cancer can safely skip surgery after chemotherapy, complementing existing imaging checks.
BACKGROUND: Non-operative management after total neoadjuvant therapy (TNT) has emerged as a potential strategy for patients with locally advanced rectal cancer (LARC) achieving clinical complete response (cCR). ctDNA should be interpreted as a complementary tool for systemic risk stratification alongside established anatomical assessment.
What the study was
- Study design
- Meta-Analysis
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- BJS open
Why it surfaced
Priority flag: EARLY_CANCER_DETECTION; Score 8/10; Design: Meta-Analysis; Topics: Early cancer detection
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.